Fig. 7: Ovarian cancer cells harboring MECOM amplification are resistant to cisplatin and gets resensitized to cisplatin upon JIB-04 pretreatment. | Cell Death Discovery

Fig. 7: Ovarian cancer cells harboring MECOM amplification are resistant to cisplatin and gets resensitized to cisplatin upon JIB-04 pretreatment.

From: Epigenetic targeting of MECOM/KRAS axis by JIB-04 impairs tumorigenesis and cisplatin resistance in MECOM-amplified ovarian cancer

Fig. 7

A, B, C Dose dependent cell viability assay for OVSAHO, SKOV3, and A2780 in response to increasing doses of cisplatin. IC50 values demonstrate that MECOM amplified ovarian cancer cell lines exhibit higher resistance to cisplatin than non-amplified cells. D SKOV3 cells were pre-treated with E-JIB-04 with indicated doses (IC20, IC30, IC40, IC50) for 24 h and then treated with 2-fold serial dilution doses of cisplatin starting from 30 µM to 0.23 µM as end concentration. The table provides IC50 values calculated for each indicated treatments. All data are plotted as mean ± SD.

Back to article page